1. Home
  2. FUL vs RCUS Comparison

FUL vs RCUS Comparison

Compare FUL & RCUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo H. B. Fuller Company

FUL

H. B. Fuller Company

HOLD

Current Price

$63.71

Market Cap

3.3B

Sector

Industrials

ML Signal

HOLD

Logo Arcus Biosciences Inc.

RCUS

Arcus Biosciences Inc.

HOLD

Current Price

$23.85

Market Cap

2.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FUL
RCUS
Founded
1887
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Home Furnishings
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.3B
2.9B
IPO Year
2007
2018

Fundamental Metrics

Financial Performance
Metric
FUL
RCUS
Price
$63.71
$23.85
Analyst Decision
Buy
Buy
Analyst Count
5
10
Target Price
$68.40
$31.90
AVG Volume (30 Days)
600.5K
956.3K
Earning Date
03-25-2026
05-05-2026
Dividend Yield
1.57%
N/A
EPS Growth
19.57
N/A
EPS
0.38
N/A
Revenue
$2,897,000,000.00
$247,000,000.00
Revenue This Year
$4.96
N/A
Revenue Next Year
$4.00
$45.62
P/E Ratio
$167.37
N/A
Revenue Growth
N/A
N/A
52 Week Low
$48.71
$7.92
52 Week High
$68.63
$28.72

Technical Indicators

Market Signals
Indicator
FUL
RCUS
Relative Strength Index (RSI) 58.45 49.25
Support Level $57.33 $23.26
Resistance Level $65.37 $24.33
Average True Range (ATR) 2.19 1.55
MACD 0.29 -0.13
Stochastic Oscillator 79.57 45.82

Price Performance

Historical Comparison
FUL
RCUS

About FUL H. B. Fuller Company

H.B. Fuller Co manufactures and sells adhesives, sealants, and other chemical-based products. The company organizes itself into three segments: Hygiene, Health and Consumable Adhesives, Engineering Adhesives, and Construction Adhesives. It generates the maximum revenue from hygiene, health, and consumable adhesives. This segment produces and supplies a full range of specialty industrial adhesives such as thermoplastic, thermoset, reactive, water-based, and solvent-based products for applications in various markets, including packaging, converting, nonwoven, and hygiene (disposable diapers, feminine care, and medical garments) and health and beauty. The company generates around half of its revenue in the United States.

About RCUS Arcus Biosciences Inc.

Arcus Biosciences Inc is a late clinical-stage biopharmaceutical company focused on developing differentiated molecules for patients with cancer and inflammatory and autoimmune diseases. Its product pipeline includes Domvanalimab, Quemliclustat, Casdatifan, Zimberelimab, among others. The company operates in one reportable and operating segment, which is the business of developing and commercializing differentiated therapies.

Share on Social Networks: